Published on : Jan 11, 2017
ALBANY, NY, Jan 11, 2017: The report, titled “PharmSource - Bio/Pharma CapEx Trends 2016,” observes that captive capacity remains the most prominent impediment for the faster growth of the contract manufacturing and development industry.
The latest PharmaSource trend report finds that in the past five years, biopharmaceutical companies have collectively endowed over US$150 bn for new equipment and plants across the world, which is more than ten times larger than what CMOs have invested in themselves during the same period. It has also been noted by the report that generic bio/pharma companies have spent heavily to build new manufacturing capacity, particularly in the emerging markets, which is a clear indication of strategic progress towards capturing the untapped market with cheap and skilled labor.
The report begins with an elaborate executive summary on the CapEx Trends and then evaluates it with other financial indicators. It further focuses on the nature of capital expenditure and while exploring what is being built, the report also analyzes its future implications. In the section on latest developments, recently completed, announced, and proposed investments by global bio/pharma companies have been provided. The report asserts added focus on emerging markets, and points out the recent and expected manufacturing investments in the upcoming markets by the prominent during the period of 2014 to 2021. It also contains a list of selected CapEx investments since 2014 by the generic companies.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=903182
The report has several quantitative tables for the players, such as composition of the PharmaSource Universe, analysis of indentified CapEx projects and their locations. The list of figures include CapEx by company sector in 2015, comparison of CapEx change to revenue change during the period of 2010 to 2015, CapEx spend and growth rate of the biopharmaceuticals companies, and capital expenditure for leading public CDMOs. This report also figuratively states the cash spend on dividends, share repurchase and CapEx by selected companies in the U.S. from 2010 to 2015.
This 16-page report is meant to serve as an asset to the CMO executives and strategic decision-makers in the biopharmaceutical industry, by providing a comprehensive insight into the figures and drivers of contract manufacturing industry. It tracks investments by major segments of the bio/pharma industry, and gives details on investments by the global and generic biopharma companies. The report also estimates the future outlook of the market, while finding out why prominent companies are adamant on favoring captive capacity. It also describes the essential role of CMOs in the bio/pharma supply chain.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org